Combined adjuvant therapy of radically operated colorectal cancer patients - (Chemotherapy, radiotherapy, and MER-BCG)

E. Robinson; A. Bartal; Y. Cohen; N. Haim; J. Mohilever; T. Mekori

doi:10.1007/BF00292869

Combined adjuvant therapy of radically operated colorectal cancer patients - (Chemotherapy, radiotherapy, and MER-BCG)

E. Robinson, A. Bartal, Y. Cohen, N. Haim, J. Mohilever, T. Mekori

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

Seventy-three patients with Dukes' B₂ and C colorectal cancer were randomized to adjuvant therapy after radical surgery. One group was treated with chemotherapy either alone or in combination with radiotherapy (RC). The second group was treated by chemotherapy (with or without radiotherapy) plus MER/BCG (RCM). In patients with Dukes' C disease, the survival at 54 months and the disease-free interval up to 24 months were significantly better in the RCM than in the RC subgroup. There were no significant differences in the survival and disease-free interval between RC- and RCM-treated patients with Dukes' B₂ disease. Entry of additional patients and further follow-up are needed before we can decide whether the combination of RCM increases the cure rate in Dukes' C cancer or merely delays recurrence and prolongs survival.

Original language	English
Pages (from-to)	35-40
Number of pages	6
Journal	Cancer Chemotherapy and Pharmacology
Volume	8
Issue number	1
DOIs	https://doi.org/10.1007/BF00292869
State	Published - 1 Jan 1982
Externally published	Yes

ASJC Scopus subject areas

Oncology
Toxicology
Pharmacology
Cancer Research
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/BF00292869

Cite this

@article{aef19e3868804ad8ae0e0c509b11766e,

title = "Combined adjuvant therapy of radically operated colorectal cancer patients - (Chemotherapy, radiotherapy, and MER-BCG)",

abstract = "Seventy-three patients with Dukes' B2 and C colorectal cancer were randomized to adjuvant therapy after radical surgery. One group was treated with chemotherapy either alone or in combination with radiotherapy (RC). The second group was treated by chemotherapy (with or without radiotherapy) plus MER/BCG (RCM). In patients with Dukes' C disease, the survival at 54 months and the disease-free interval up to 24 months were significantly better in the RCM than in the RC subgroup. There were no significant differences in the survival and disease-free interval between RC- and RCM-treated patients with Dukes' B2 disease. Entry of additional patients and further follow-up are needed before we can decide whether the combination of RCM increases the cure rate in Dukes' C cancer or merely delays recurrence and prolongs survival.",

author = "E. Robinson and A. Bartal and Y. Cohen and N. Haim and J. Mohilever and T. Mekori",

year = "1982",

month = jan,

day = "1",

doi = "10.1007/BF00292869",

language = "English",

volume = "8",

pages = "35--40",

journal = "Cancer Chemotherapy and Pharmacology",

issn = "0344-5704",

publisher = "Springer Verlag",

number = "1",

}

TY - JOUR

T1 - Combined adjuvant therapy of radically operated colorectal cancer patients - (Chemotherapy, radiotherapy, and MER-BCG)

AU - Robinson, E.

AU - Bartal, A.

AU - Cohen, Y.

AU - Haim, N.

AU - Mohilever, J.

AU - Mekori, T.

PY - 1982/1/1

Y1 - 1982/1/1

N2 - Seventy-three patients with Dukes' B2 and C colorectal cancer were randomized to adjuvant therapy after radical surgery. One group was treated with chemotherapy either alone or in combination with radiotherapy (RC). The second group was treated by chemotherapy (with or without radiotherapy) plus MER/BCG (RCM). In patients with Dukes' C disease, the survival at 54 months and the disease-free interval up to 24 months were significantly better in the RCM than in the RC subgroup. There were no significant differences in the survival and disease-free interval between RC- and RCM-treated patients with Dukes' B2 disease. Entry of additional patients and further follow-up are needed before we can decide whether the combination of RCM increases the cure rate in Dukes' C cancer or merely delays recurrence and prolongs survival.

AB - Seventy-three patients with Dukes' B2 and C colorectal cancer were randomized to adjuvant therapy after radical surgery. One group was treated with chemotherapy either alone or in combination with radiotherapy (RC). The second group was treated by chemotherapy (with or without radiotherapy) plus MER/BCG (RCM). In patients with Dukes' C disease, the survival at 54 months and the disease-free interval up to 24 months were significantly better in the RCM than in the RC subgroup. There were no significant differences in the survival and disease-free interval between RC- and RCM-treated patients with Dukes' B2 disease. Entry of additional patients and further follow-up are needed before we can decide whether the combination of RCM increases the cure rate in Dukes' C cancer or merely delays recurrence and prolongs survival.

UR - http://www.scopus.com/inward/record.url?scp=0020068319&partnerID=8YFLogxK

U2 - 10.1007/BF00292869

DO - 10.1007/BF00292869

M3 - Article

AN - SCOPUS:0020068319

SN - 0344-5704

VL - 8

SP - 35

EP - 40

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

IS - 1

ER -

Combined adjuvant therapy of radically operated colorectal cancer patients - (Chemotherapy, radiotherapy, and MER-BCG)

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this